The historical rank and industry rank for Relief Therapeutics Holding's Cyclically Adjusted PS Ratio or its related term are showing as below:
XSWX:RLF'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.01 Med: 0.28 Max: 19.88
Current: 7.87
During the past 13 years, Relief Therapeutics Holding's highest Cyclically Adjusted PS Ratio was 19.88. The lowest was 0.01. And the median was 0.28.
XSWX:RLF's Cyclically Adjusted PS Ratio is not ranked
in the Biotechnology industry.
Industry Median: 5.57
vs XSWX:RLF: 7.87
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Relief Therapeutics Holding's adjusted revenue per share data of for the fiscal year that ended in Dec24 was CHF0.671. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is CHF0.38 for the trailing ten years ended in Dec24.
Shiller PE for Stocks: The True Measure of Stock Valuation
Relief Therapeutics Holding (XSWX:RLF) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Relief Therapeutics Holding Cyclically Adjusted PS Ratio Related Terms
Relief Therapeutics Holding Cyclically Adjusted PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Relief Therapeutics Holding Cyclically Adjusted PS Ratio Chart
XSWX:RLF vs KTTA, OSRH, LIMN: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, Relief Therapeutics Holding's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Relief Therapeutics Holding Cyclically Adjusted PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Relief Therapeutics Holding's Cyclically Adjusted PS Ratio falls into.
Relief Therapeutics Holding Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 7.89 mean?
Relief Therapeutics Holding (XSWX:RLF) has a Cyclically Adjusted PS Ratio of 7.89 as of Jul. 05, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Relief Therapeutics Holding and its competitors. This is 2718% above median its historical median of 0.28. Over the past decade, Relief Therapeutics Holding's Cyclically Adjusted PS Ratio has ranged from 0.01 to 19.88.
Is Relief Therapeutics Holding's Cyclically Adjusted PS Ratio too high?
Relief Therapeutics Holding's current Cyclically Adjusted PS Ratio of 7.89 is 2718% above median its 10-year median of 0.28. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 19.88. The Biotechnology industry median Cyclically Adjusted PS Ratio is 5.57. Relief Therapeutics Holding's value of 7.89 is 41.7% above this industry median. Overall, Relief Therapeutics Holding has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Relief Therapeutics Holding's Cyclically Adjusted PS Ratio compare to KTTA and OSRH?
Relief Therapeutics Holding's Cyclically Adjusted PS Ratio of 7.89 can be compared against companies in the Biotechnology industry. The industry median Cyclically Adjusted PS Ratio is 5.57. Relief Therapeutics Holding's value of 7.89 is 41.7% above this benchmark. Historically, Relief Therapeutics Holding's own Cyclically Adjusted PS Ratio has ranged from 0.01 to 19.88 over the past decade. While the company's 10-year median is 0.28 vs. the industry median of 5.57, Relief Therapeutics Holding has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 5.57, based on 537 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Relief Therapeutics Holding's current Cyclically Adjusted PS Ratio of 7.89 is 41.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Relief Therapeutics Holding and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 5.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Relief Therapeutics Holding's current Cyclically Adjusted PS Ratio is 7.89, which is 2718% above median its own 10-year median of 0.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relief Therapeutics Holding stock overvalued right now?
Relief Therapeutics Holding (XSWX:RLF) has a current Cyclically Adjusted PS Ratio of 7.89. The stock's GF Value™ is CHF6.28, compared to a current price of CHF3.00 — trading 52.2% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 7.89, which is 2718% above median its 10-year median of 0.28 and 41.7% above the Biotechnology industry median of 5.57. Relief Therapeutics Holding's overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Relief Therapeutics Holding (XSWX:RLF), the current Cyclically Adjusted PS Ratio is 7.89 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Relief Therapeutics Holding (XSWX:RLF) Overvalued in 2026?
Based on GuruFocus' analysis, Relief Therapeutics Holding stock appears to be undervalued.
The current stock price of CHF3.00 is trading 52.2% below its estimated GF Value™ of CHF6.28.
Key valuation signals for XSWX:RLF:
Cyclically Adjusted PS Ratio: 7.89 (2718% above median its 10-year median of 0.28)
GF Value™: CHF6.28 vs. price of CHF3.00 (52.2% below fair value)
Industry Position: 41.7% above the Biotechnology median
No single metric tells the full story. See the XSWX:RLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.
20GF Score
Get the complete analysis for XSWX:RLF
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:RLF has been successfully added to your 
